AdvaMed makes use of Senate debate with medtech survey
This article was originally published in Clinica
Executive Summary
European regulators received higher marks than the FDA in a new survey released last week by AdvaMed. Three out of four device companies polled claimed they can get their technologies to market faster in Europe than in the US, while only 5% reported the opposite experience. The remaining 19% said there was no difference in product development times between the two jurisdictions.